deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03698552

ADCT-602 in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia

A Phase I/II Study to Evaluate the Safety and Anti-Tumor Activity of ADCT-602 Targeting CD22 in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Sponsor: ADC Therapeutics S.A.

Conditions Blasts 5 Percent or More of Bone Marrow Nucleated Cells CD22 Positive Philadelphia Chromosome Positive Recurrent B Acute Lymphoblastic Leukemia Refractory B Acute Lymphoblastic Leukemia
Interventions ADCT-602
Updated 22 times since 2018 Last updated: Dec 9, 2025 Started: Aug 24, 2018 Primary completion: Nov 6, 2025 Completion: Nov 6, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

\<75% participation

Other terminated trials from ADC Therapeutics S.A.

More terminations from ADC Therapeutics S.A.

Listed as NCT03698552, this PHASE1/PHASE2 trial focuses on Blasts 5 Percent or More of Bone Marrow Nucleated Cells and CD22 Positive and remains terminated or withdrawn. Sponsored by ADC Therapeutics S.A., it has been updated 22 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Nov 2018 – ~Dec 2019 · 13 months · monthly snapshot~Dec 2019 – ~Mar 2020 · 3 months · monthly snapshot~Mar 2020 – ~Jun 2020 · 3 months · monthly snapshot~Jun 2020 – ~Sep 2020 · 3 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Feb 2022 · 5 months · monthly snapshot~Feb 2022 – ~Sep 2022 · 7 months · monthly snapshot~Sep 2022 – ~Jan 2023 · 4 months · monthly snapshot~Jan 2023 – ~Jul 2023 · 6 months · monthly snapshot~Jul 2023 – ~Nov 2023 · 4 months · monthly snapshot~Nov 2023 – ~Apr 2024 · 5 months · monthly snapshot~Apr 2024 – ~Jun 2024 · 2 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Dec 2024 · 30 days · monthly snapshot~Dec 2024 – ~Jun 2025 · 6 months · monthly snapshot~Jun 2025 – ~Dec 2025 · 6 months · monthly snapshot~Dec 2025 – ~Jan 2026 · 31 days · monthly snapshot~Jan 2026 – present · 6 months · monthly snapshot

Change History

22 versions recorded

  1. Jan 2026 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Dec 2025 — Jan 2026 [monthly]

    Terminated PHASE1/PHASE2

    Status: Recruiting → Terminated

  3. Jun 2025 — Dec 2025 [monthly]

    Recruiting PHASE1/PHASE2

  4. Dec 2024 — Jun 2025 [monthly]

    Recruiting PHASE1/PHASE2

  5. Nov 2024 — Dec 2024 [monthly]

    Recruiting PHASE1/PHASE2

▶ Show 17 earlier versions

  1. Sep 2024 — Nov 2024 [monthly]

    Recruiting PHASE1/PHASE2

  2. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE1/PHASE2

  3. Jul 2024 — Aug 2024 [monthly]

    Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Jun 2024 — Jul 2024 [monthly]

    Recruiting PHASE1_PHASE2

  5. Apr 2024 — Jun 2024 [monthly]

    Recruiting PHASE1_PHASE2

  6. Nov 2023 — Apr 2024 [monthly]

    Recruiting PHASE1_PHASE2

  7. Jul 2023 — Nov 2023 [monthly]

    Recruiting PHASE1_PHASE2

  8. Jan 2023 — Jul 2023 [monthly]

    Recruiting PHASE1_PHASE2

  9. Sep 2022 — Jan 2023 [monthly]

    Recruiting PHASE1_PHASE2

  10. Feb 2022 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  11. Sep 2021 — Feb 2022 [monthly]

    Recruiting PHASE1_PHASE2

  12. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE1_PHASE2

  13. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  14. Jun 2020 — Sep 2020 [monthly]

    Recruiting PHASE1_PHASE2

  15. Mar 2020 — Jun 2020 [monthly]

    Recruiting PHASE1_PHASE2

  16. Dec 2019 — Mar 2020 [monthly]

    Recruiting PHASE1_PHASE2

  17. Nov 2018 — Dec 2019 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Aug 2018

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • ADC Therapeutics S.A.
  • M.D. Anderson Cancer Center
  • National Cancer Institute (NCI)
Data source: M.D. Anderson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations